Inventor · disambiguated record
Dean Russell Kahn
Also filed as: KAHN DEAN · KAHN DEAN RUSSELL
7 granted patents·4 pending applications·20 citations·filing 2019–2025
78Inventor score
Top patents by PatentIndex Score
11 records- 0196US11453683B1KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·13 cites·84 claims
- 0294US11414404B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2020·Granted Aug 16, 2022·5 cites·14 claims
- 0392US11964989B2KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·2 cites·19 claims
- 0477US2024309020A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0571US11634409B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2022·Granted Apr 25, 2023·0 cites·42 claims
- 0668US12303509B2Compounds for the treatment of BRAF-associated diseases and disordersPFIZER·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 0762US2025241915A1Compounds for the treatment of braf-associated diseases and disordersPFIZER·Filed 2025·Application pending·0 cites
- 0855US2023357277A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0953US2023279025A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1049US11472802B2Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Oct 18, 2022·0 cites·11 claims
- 1147US11964988B2Fused heterocyclic compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Apr 23, 2024·0 cites·18 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →